Skip to main content

Table 3 HCV PCR of the studied group at weeks 24 and 36 of DAA therapy

From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus

PCR Week 0 Week 24 (SVR 12) Week 36 (SVR24)
N % N % N %
Positive 50 100.00 2 4.00 4 8.00
Negative 0 0.00 48 96.00 46 92
Total 50 100.00 50 100.00 50 100.00